Vanta Bioscience Ltd
Incorporated in 2016, Vanta Bioscience
Ltd is in the business of Preclinical Activities.[1]
- Market Cap ₹ 18.1 Cr.
- Current Price ₹ 25.5
- High / Low ₹ 50.3 / 19.1
- Stock P/E
- Book Value ₹ 27.1
- Dividend Yield 0.00 %
- ROCE -11.6 %
- ROE -37.2 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Stock is trading at 0.92 times its book value
Cons
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -32.3% over past five years.
- Company has a low return on equity of -27.2% over last 3 years.
- Company has high debtors of 466 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Half Yearly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|
| 12.08 | 13.75 | 9.82 | 9.40 | 5.83 | 9.72 | 1.96 | 1.23 | |
| 8.81 | 9.38 | 5.87 | 5.93 | 8.22 | 8.41 | 6.21 | 5.48 | |
| Operating Profit | 3.27 | 4.37 | 3.95 | 3.47 | -2.39 | 1.31 | -4.25 | -4.25 |
| OPM % | 27.07% | 31.78% | 40.22% | 36.91% | -40.99% | 13.48% | -216.84% | -345.53% |
| 0.23 | 0.11 | 0.03 | 0.42 | 0.69 | 0.11 | 0.11 | 0.07 | |
| Interest | 1.69 | 1.95 | 2.14 | 2.35 | 5.89 | 5.75 | 4.07 | 2.80 |
| Depreciation | 0.71 | 1.19 | 1.25 | 1.32 | 2.67 | 4.50 | 4.42 | 3.34 |
| Profit before tax | 1.10 | 1.34 | 0.59 | 0.22 | -10.26 | -8.83 | -12.63 | -10.32 |
| Tax % | 36.36% | 24.63% | 23.73% | 40.91% | 1.75% | -2.49% | 5.23% | |
| 0.70 | 1.01 | 0.45 | 0.14 | -10.44 | -8.61 | -13.29 | -4.53 | |
| EPS in Rs | 1.11 | 1.58 | 0.71 | 0.14 | -10.27 | -3.68 | -7.56 | -6.85 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -32% |
| 3 Years: | -41% |
| TTM: | -73% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -18% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | -30% |
| 3 Years: | -30% |
| 1 Year: | -39% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | -13% |
| 3 Years: | -27% |
| Last Year: | -37% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 6.31 | 6.31 | 6.31 | 6.31 | 6.31 | 6.31 | 6.31 | 7.11 |
| Reserves | 15.94 | 17.16 | 17.61 | 17.70 | 11.20 | 8.89 | 4.11 | 12.14 |
| 13.25 | 17.37 | 35.97 | 44.86 | 57.16 | 60.96 | 70.09 | 30.57 | |
| 3.51 | 7.74 | 9.74 | 12.53 | 10.04 | 9.24 | 5.37 | 7.04 | |
| Total Liabilities | 39.01 | 48.58 | 69.63 | 81.40 | 84.71 | 85.40 | 85.88 | 56.86 |
| 17.90 | 20.76 | 29.39 | 36.12 | 57.22 | 54.15 | 55.50 | 41.82 | |
| CWIP | 3.70 | 7.00 | 19.34 | 28.47 | 10.60 | 12.53 | 13.47 | 0.00 |
| Investments | 1.95 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.00 |
| 15.46 | 20.82 | 20.90 | 16.81 | 16.89 | 18.72 | 16.91 | 12.04 | |
| Total Assets | 39.01 | 48.58 | 69.63 | 81.40 | 84.71 | 85.40 | 85.88 | 56.86 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|
| -1.04 | 2.34 | 6.97 | 5.28 | -0.63 | 2.68 | -2.41 | |
| -5.73 | -7.59 | -22.30 | -17.24 | -5.91 | -3.31 | -6.69 | |
| 9.94 | 2.17 | 17.78 | 9.53 | 6.41 | 0.69 | 9.16 | |
| Net Cash Flow | 3.18 | -3.07 | 2.46 | -2.43 | -0.13 | 0.06 | 0.06 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|
| Debtor Days | 47.14 | 36.90 | 74.71 | 43.88 | 122.71 | 117.91 | 465.56 |
| Inventory Days | 2,400.15 | ||||||
| Days Payable | 1,821.31 | ||||||
| Cash Conversion Cycle | 47.14 | 36.90 | 74.71 | 43.88 | 122.71 | 117.91 | 1,044.40 |
| Working Capital Days | 260.76 | 259.61 | 91.06 | -135.13 | -163.40 | -217.42 | -2,126.68 |
| ROCE % | 8.35% | 5.21% | 3.77% | -5.82% | -4.16% | -11.58% |
Documents
Announcements
- Financial Results For The Half Year Ended September 30, 2025 14 Nov
-
Board Meeting Outcome for Outcome Of The Board Meeting Held On November 14, 2025
14 Nov - Board approved unaudited standalone and consolidated results for half-year ended Sep 30, 2025; limited review attached.
-
Board Meeting Intimation for Board Meeting To Be Held On 14.11.2025
8 Nov - Board meeting Nov 14, 2025 to approve unaudited H1 results ended Sep 30, 2025; trading window Oct1–Nov16.
-
Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer
1 Nov - Ms Sangeetha Padam Choudhary resigned as Company Secretary & Compliance Officer effective 01-Nov-2025 to pursue career growth.
-
Reg. 34 (1) Annual Report.
1 Nov - Annual Report 2024-25 and Notice of 9th AGM (Sept 30, 2025) uploaded to website and filed with BSE.
Business Overview:[1]
The company is a preclinical contract research organization, offering preclinical safety assessment services for clientele from the Pharmaceutical, Medical Devices, Nutraceuticals, Feed additives, Biotech, Agrochemicals, Cosmetics, and Chemical industries. In addition, the company also provides risk assessment services for evaluating the safety of Active Pharmaceutical Ingredients (API), excipients, extractable and leachable including pharmaceutical impurities resulting due to manufacturing process or degradation
of the product. VBS also provides expert services for the determination of health-based exposure limits e.g. permitted daily exposure or allowable daily exposure (ADE) including occupational exposure limits (OEL) for pharmaceutical manufacturers.
Services Offered:
a) Toxicology[2]
b) Agro-chemical and Chemical Safety[3]
c) Bio Compatibility Studies[4]
d) Diet Formulation[5]
e) Batch Release Test[6]
f) Medical Devices[7]
g) Food Additives[8]
h) Cosmetics[9]